Savara Inc. Shareholders Who Lost Money in SVRA Should Contact Robbins LLP for Information About Leading the Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Allegations - The lawsuit claims that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [2]. - The complaint also states that the company was unlikely to meet its previously communicated timeline for submitting the MOLBREEVI BLA, and the delay increased the likelihood of needing additional capital [2]. Stock Price Impact - Following the announcement of a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by November 7, 2025, although they can remain absent class members if they choose not to take action [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].